DOI : 10.1055/s-00000059

Pneumologie

Issue S 01 · Volume 69 · March 2015 DOI: 10.1055/s-005-28563


56. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
Berlin, 18.–21. 3. 2015

Kongresspräsident: Prof. Dr. med. Torsten T. Bauer, Berlin

P155
Kahn, N; Meister, M; Eberhardt, R; Muley, T; Oltmanns, U; Baroke, E; Palmowski, K; Herth, FJF; Kreuter, M: MicroRNA Expressions-Profile von epithelialer Lining Fluid (ELF) und bronchoalveolärer Lavage (BAL) bei idiopathischer Lungenfibrose (IPF)
P158
Kreuter, M; Günther, A; Leidl, R; Hellmann, A; Pfeifer, M; Behr, J; Wacker, M; Witt, S; Kauschka, D; Mall, M; Herth, FJF; Markart, P: Interimsanalyse des EXCITING-ILD Registers (Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases)
P159
Ehlers-Tenenbaum, S; Palmowski, K; Oltmanns, U; Muley, T; Baroke, E; Warth, A; Schnabel, PA; Heußel, CP; Herth, FJF; Kreuter, M: Ein Komorbiditäten Hazard Ratio Score als prognostischer Faktor bei der idiopathischen Lungenfibrose (IPF)
P194
Kreuter, M; Kirsten, D; Bahmer, T; Penzel, R; Claussen, M; Oltmanns, U; Ehlers-Tenenbaum, S; Muley, T; Palmowski, K; Kugler, C; Baroke, E; Eichinger, M; Schnabel, PA; Heussel, CP; Herth, FJF; Rabe, KF; Bittmann, I; Warth, A: Untersuchung von Lungenbiopsien bei Patienten mit interstitiellen Lungenerkrankungen (ILD) auf Helicobater pylori mittels PCR
P205
Behr, J; Kreuter, M; Pittrow, D; Hoeper, MM; Klotsche, J; Koschel, D; Andreas, S; Neurohr, C; Grohé, C; Claussen, M; Wilkens, H; Randerath, WJ; Skowasch, D; Kirschner, J; Koch, A; Meyer, FJ; Ewert, R; Welte, T; Held, M; Schwaiblmair, M; Gamarra, F; Herth, FJF; Huber, RM; Wirtz, H: Klinischer Verlauf von Patienten mit Idiopathischer Lungenfibrose in der klinischen Praxis: INSIGHTS-IPF Register
P217
Priegnitz, C; Hagmeyer, L; Kietzmann, I; Randerath, WJ: Spiroergometrie bei interstitiellen Lungenerkrankungen
P234
Costabel, U; Richeldi, L; Azuma, A; Inoue, Y; Collard, HR; Tschoepe, I; Stowasser, S; Selman, M: Pre-specified subgroup analyses of pooled data from the INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis
P235
Costabel, U; Richeldi, L; du Bois, RM; Raghu, G; Azuma, A; Brown, KK; Cottin, V; Flaherty, KR; Inoue, Y; Kim, DS; Kolb, M; Noble, PW; Selman, M; Taniguchi, H; Brun, M; Girard, M; Schlenker-Herceg, R; Disse, B; Collard, HR: Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™)
P244
Costabel, U; Kolb, M; Inoue, Y; Hernandez, P; Bailes, Z; Schlenker-Herceg, R; Azuma, A: Effect of FEV1/FVC ratio on reduction in FVC decline with nintedanib in the INPULSIS™ trials
P246
Kirsten, AM; Richeldi, L; Roman, J; Le Maulf, F; Hallmann, C; Stowasser, S; Lasky, JA: Pooled analysis of mortality data from the TOMORROW and INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (IPF)
P252
Kreuter, M; Cottin, V; Taniguchi, H; Collard, HR; Richeldi, L; Stowasser, S; Tschoepe, I; Schlenker-Herceg, R; Raghu, G: Reduction in disease progression with nintedanib in the INPULSIS™ trials
P253
Neurohr, C; Kolb, M; Collard, HR; Stowasser, S; Girard, M; Schlenker-Herceg, R; Richeldi, L: Sensitivity analyses from the INPULSIS™ trials of nintedanib
P254
Pfeifer, M; Cottin, V; Taniguchi, H; Richeldi, L; Collard, HR; Kaye, M; Hansell, DM; Bailes, Z; Schlenker-Herceg, R; Raghu, G: Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials
P313
Westhoff, M; Bach, P: PET-CT bei Lungenfibrose